Dr Reddy’s Launches Ziprasidone Mesylate Into Marke
Hyderabad, March 17 (Maxim News): Dr. Reddy’s Laboratories Ltd. said launch of Ziprasidone Mesylate for Injection, 20 mg (base)/mL Single-dose Vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration (USFDA).
“We’re pleased to bring the first generic of Ziprasidone Mesylate for Injection to market for patients who will benefit from access to affordable medicine. With every new product launch, we believe we are making healthcare more affordable by delivering value to the pharmacy,” explained Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio and drive growth within the hospital segment.”
The Geodon brand had U.S. sales of approximately $21.8 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.(Maxim News)